scholarly journals Correction to: Two Pituitary Neuroendocrine Tumors (PitNETs) with Very High Proliferation and TP53 Mutation – High‑Grade PitNET or PitNEC?

2021 ◽  
Author(s):  
Wolfgang Saeger ◽  
Christian Mawrin ◽  
Matthias Meinhardt ◽  
Annika K. Wefers ◽  
Frank Jacobsen
Keyword(s):  
Neuroendocrine Tumors ◽  
Tp53 Mutation ◽  
High Grade ◽  
Very High

scholarly journals Emerging Therapeutic Concepts and Latest Diagnostic Advancements Regarding Neuroendocrine Tumors of the Gynecologic Tract

Medicina ◽  
2021 ◽  
Vol 57 (12) ◽  
pp. 1338
Author(s):  
Tiberiu-Augustin Georgescu ◽  
Roxana Elena Bohiltea ◽  
Octavian Munteanu ◽  
Florentina Furtunescu ◽  
Antonia-Carmen Lisievici ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Neuroendocrine Carcinoma ◽  
Classification System ◽  
Who Classification ◽  
Small Cell ◽  
International Agency ◽  
Low Grade ◽  
High Grade ◽  
Small Cell Neuroendocrine Carcinoma ◽  
Female Genital

Neuroendocrine neoplasms (NENs) are particularly rare in all sites of the gynecological tract and include a variety of neoplasms with variable prognosis, dependent on histologic subtype and site of origin. Following the expert consensus proposal of the International Agency for Research on Cancer (IARC), the approach in the latest World Health Organization (WHO) Classification System of the Female Genital Tumours is to use the same terminology for NENs at all body sites. The main concept of this novel classification framework is to align it to all other body sites and make a clear distinction between well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs). The previous WHO Classification System of the Female Genital Tumours featured more or less the same principle, but used the terms ‘low-grade neuroendocrine tumor’ and ‘high-grade neuroendocrine carcinoma’. Regardless of the terminology used, each of these two main categories include two distinct morphological subtypes: NETs are represented by typical and atypical carcinoid and NEC are represented by small cell neuroendocrine carcinoma (SCNEC) and large cell neuroendocrine carcinoma (LCNEC). High-grade NECs, especially small cell neuroendocrine carcinoma tends to be more frequent in the uterine cervix, followed by the endometrium, while low-grade NETs usually occur in the ovary. NENs of the vulva, vagina and fallopian tube are exceptionally rare, with scattered case reports in the scientific literature.

scholarly journals Lanreotide for the treatment of patients with disseminated high-grade neuroendocrine tumors: the experience of application in case of unsatisfactory tolerability of octreotide

2016 ◽  
Vol 18 (1) ◽  
pp. 80-83
Author(s):  
G.S. Emelyanova ◽  
◽  
A.E. Kuzminov ◽  
N.F. Orel ◽  
A.S. Odintsova ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
High Grade

scholarly journals P1.12-05 Efficacy of Perioperative Chemotherapy for High-Grade Neuroendocrine Tumors

2018 ◽  
Vol 13 (10) ◽  
pp. S574-S575
Author(s):  
H. Ogawa ◽  
Y. Tanaka ◽  
Y. Kitamura ◽  
H. Tanaka ◽  
Y. Nishioka ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
High Grade ◽  
Perioperative Chemotherapy

scholarly journals Stathmin-1 Is a Useful Diagnostic Marker for High-Grade Lung Neuroendocrine Tumors

2019 ◽  
Vol 108 (1) ◽  
pp. 235-243
Author(s):  
Kimihiro Shimizu ◽  
Yusuke Goto ◽  
Reika Kawabata-Iwakawa ◽  
Yoichi Ohtaki ◽  
Seshiru Nakazawa ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Diagnostic Marker ◽  
High Grade ◽  
Stathmin 1

scholarly journals Amphicrine carcinoma of the stomach and intestine: a clinicopathologic and pan-cancer transcriptome analysis of a distinct entity

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Dan Huang ◽  
Fei Ren ◽  
Shujuan Ni ◽  
Cong Tan ◽  
Weiwei Weng ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Expression Patterns ◽  
Biological Behavior ◽  
Low Grade ◽  
High Grade ◽  
Clinicopathologic Characteristics ◽  
Signet Ring ◽  
Cancer Transcriptome ◽  
Male Patients ◽  
Pan Cancer

Abstract Background and aim Amphicrine carcinoma, in which endocrine and epithelial cell constituents are present within the same cell, is very rare. This study characterized the clinicopathologic and survival analysis of this tumor, further compared the genetic diversities among amphicrine carcinoma and other tumors. Materials and methods The clinicopathologic characteristics and survival outcomes of amphicrine carcinoma in this study were analyzed. The pan-cancer transcriptome assay was utilized to compare the genetic expression profile of this entity with that of conventional adenocarcinoma or neuroendocrine tumors. Results Ten cases (all in male patients) were identified in the stomach or intestine, with a median patient age of 62 years. There were characteristic patterns in the tumors: tubular, fusion or single-file growth of goblet- or signet ring-like cells. Four tumors were classified as low-grade and 6 as high-grade according to the histologic architecture. All cases were positive for neuroendocrine markers (synaptophysin and chromogranin A) and showed intracellular mucin in the amphicrine components. Four cases exhibited mRNA expression patterns showing transcriptional homogeneity with conventional adenocarcinomas and genetic diversity from neuroendocrine tumors. During the follow-up period, 3 patients died of disease, all of whom had high-grade tumors. Patients with high-grade amphicrine carcinoma had worse outcomes than those with low-grade tumors. Conclusions This study confirms the morphological, immunostaining and transcriptome alterations in amphicrine carcinoma distinct from those in conventional adenocarcinomas and neuroendocrine tumors, but additional studies are warranted to determine the biological behavior and therapeutic response.

scholarly journals Molecular Characterization and Clinical Outcomes of Primary Gleason Pattern 5 Prostate Cancer After Radical Prostatectomy

2019 ◽  
pp. 1-13 ◽  
Author(s):  
Pedro Isaacsson Velho ◽  
David Lim ◽  
Hao Wang ◽  
Jong Chul Park ◽  
Harsimar B. Kaur ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radical Prostatectomy ◽  
Homologous Recombination ◽  
Tp53 Mutation ◽  
Castration Resistance ◽  
Repair Gene ◽  
Pten Loss ◽  
Gleason Pattern ◽  
Very High

Purpose Very high-risk prostate cancer (PC) is associated with poor response to local and systemic treatments; however, few cases have been molecularly profiled. We studied clinical outcomes and molecular profiles of patients with clinically localized primary Gleason pattern 5 PC. Patients and Methods Clinicopathologic features, targeted somatic and germline sequencing, and PTEN, TP53, and ERG status by immunohistochemistry were assessed in patients undergoing surgery from 2005 to 2015; 60 consecutive patients were identified with Gleason score 5 + 4 = 9 or 5 + 5 = 10 PC after radical prostatectomy with available tissue and clinical follow-up. Clinicopathologic and genomic parameters were correlated with biochemical relapse, metastasis-free survival, time to castration resistance, and overall survival using Cox proportional hazards models. Results Of patients with somatic sequencing data and clinical follow-up, 34% had DNA repair gene mutations, including 22% (11 of 49) with homologous recombination and 12% (six of 49) with mismatch repair gene alterations. Homologous recombination mutations were germline in 82% (nine of 11) of patients. In addition, 33% (16 of 49) had TP53 mutation, and 51% (29 of 57) had PTEN loss. Overall, 43% developed metastasis, with a time to castration resistance of 12 months. On multivariable analysis of clinicopathologic variables, only ductal/intraductal histology (hazard ratio, 4.43; 95% CI, 1.76 to 11.15; P = .002) and seminal vesicle invasion (hazard ratio, 5.14; 95% CI, 1.83 to 14.47; P = .002) were associated with metastasis. Among genomic alterations, only TP53 mutation and PTEN loss were associated with metastasis on univariable analysis, and neither remained significant in multivariable analyses. These data are retrospective and hypothesis generating. Conclusion Potentially actionable homologous recombination and mismatch repair alterations are observed in a significant proportion of patients with very high-risk PC at the time of radical prostatectomy. These findings could inform the design of prospective trials in this patient population.

Ga-68 DOTATATE PET/CT and F-18 FDG PET/CT in the evaluation of low and intermediate versus high-grade neuroendocrine tumors

2020 ◽  
Vol 41 (10) ◽  
pp. 1060-1065
Author(s):  
Helena You ◽  
Asha Kandathil ◽  
Muhammad Beg ◽  
Lorraine De Blanche ◽  
Syed Kazmi ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Fdg Pet ◽  
High Grade ◽  
Pet Ct ◽  
Fdg Pet Ct
Sign in / Sign up

Export Citation Format

Share Document